Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from PREPARE-IBD

ATU-3 Frigure 1ConclusionsOur data provide reassurance for the continued evidence-based use of corticosteroids, immunomodulators and biologic therapies in IBD during the ongoing COVID-19 pandemic, and is consistent with an as yet unexplained association between mesalazine use and severe COVID-19 outcomes.